About Xencor Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://xencor.com/
Frequently Asked Questions
What is the 52-week range for XNCR?
The 52-week high is $30.61 and the 52-week low is $10.375.
What is the P/E ratio for XNCR?
The P/E ratio data is currently unavailable.
What is the dividend yield for XNCR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -28.66%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -155.59%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.72.
Analyst Recommendation Trends
Wall Street analyst consensus for XNCR over the last few months:
Latest XNCR News
Raymond James Updates Healthcare Top Picks for October
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29
Truist Securities analyst Gregory Renza reiterates Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $27 to $29.
B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26
B of A Securities analyst Alec Stranahan maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $20 to $26.
Barclays Maintains Overweight on Xencor, Raises Price Target to $35
Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $27 to $35.
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE
JP Morgan Maintains Neutral on Xencor, Raises Price Target to $21
JP Morgan analyst Brian Cheng maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $14 to $21.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-18 | Feigal Ellen | -6,843 | $13.06 | $89,370 |
| 2026-06-16 | Deshaies Raymond Joseph | +20,604 | - | - |
| 2026-06-16 | Deshaies Raymond Joseph | +10,302 | - | - |
| 2026-06-16 | Feigal Ellen | +20,604 | - | - |
| 2026-06-16 | Feigal Ellen | +10,302 | - | - |
| 2026-06-16 | Klencke Barbara | +20,604 | - | - |
| 2026-06-16 | Klencke Barbara | +10,302 | - | - |
| 2026-06-16 | GUSTAFSON KURT A | +20,604 | - | - |
| 2026-06-16 | GUSTAFSON KURT A | +10,302 | - | - |
| 2026-06-16 | Montgomery Alan Bruce | +20,604 | - | - |
| 2026-06-16 | Montgomery Alan Bruce | +10,302 | - | - |
| 2026-06-16 | RANIERI RICHARD J | +20,604 | - | - |
| 2026-06-16 | RANIERI RICHARD J | +10,302 | - | - |
| 2026-06-16 | SIMPSON TODD E | +20,604 | - | - |
| 2026-06-16 | SIMPSON TODD E | +10,302 | - | - |
| 2026-06-16 | GORMAN KEVIN CHARLES | +20,604 | - | - |
| 2026-06-16 | GORMAN KEVIN CHARLES | +10,302 | - | - |
| 2026-06-15 | GUSTAFSON KURT A | -5,474 | $12.31 | $67,385 |
| 2026-06-15 | Montgomery Alan Bruce | -5,064 | $12.31 | $62,338 |
| 2026-06-15 | RANIERI RICHARD J | -5,474 | $12.31 | $67,385 |
| 2026-06-15 | GORMAN KEVIN CHARLES | -7,527 | $12.31 | $92,657 |
| 2026-04-10 | Cornelissen Bart Jan | -3,499 | $12.2865 | $42,990 |
| 2026-03-06 | Eckert Celia | -1,767 | $11.0197 | $19,472 |
| 2026-03-06 | Desjarlais John R | -2,502 | $11.0197 | $27,571 |
| 2026-03-06 | Dahiyat Bassil I | -6,606 | $11.0197 | $72,796 |
| 2026-03-05 | Cornelissen Bart Jan | -2,517 | $11.2455 | $28,305 |
| 2026-03-05 | Eckert Celia | -3,244 | $11.2455 | $36,480 |
| 2026-03-05 | Desjarlais John R | -4,118 | $11.2455 | $46,309 |
| 2026-03-05 | Dahiyat Bassil I | -14,870 | $11.2455 | $167,221 |
| 2026-03-03 | Eckert Celia | -1,492 | $11.8951 | $17,747 |
| 2026-03-03 | Desjarlais John R | -2,663 | $11.8951 | $31,677 |
| 2026-03-03 | Dahiyat Bassil I | -6,758 | $11.8951 | $80,387 |
| 2026-03-02 | Cornelissen Bart Jan | +116,750 | - | - |
| 2026-03-02 | Cornelissen Bart Jan | +19,458 | - | - |
| 2026-03-02 | Eckert Celia | +112,080 | - | - |
| 2026-03-02 | Eckert Celia | +18,680 | - | - |
| 2026-03-02 | Desjarlais John R | +149,440 | - | - |
| 2026-03-02 | Desjarlais John R | +24,907 | - | - |
| 2026-03-02 | Dahiyat Bassil I | +583,748 | - | - |
| 2026-03-02 | Dahiyat Bassil I | +97,291 | - | - |
| 2026-01-23 | Desjarlais John R | -5,322 | - | - |
| 2026-01-23 | Desjarlais John R | +5,322 | $12.51 | $66,578 |
| 2025-12-22 | Desjarlais John R | -6,311 | - | - |
| 2025-12-22 | Desjarlais John R | +6,311 | $12.51 | $78,951 |
| 2025-12-22 | Dahiyat Bassil I | -10,624 | - | - |
| 2025-12-22 | Dahiyat Bassil I | +10,624 | $12.51 | $132,906 |
| 2025-12-19 | Desjarlais John R | -73,367 | - | - |
| 2025-12-19 | Desjarlais John R | -73,367 | $15.72 | $1,153,329 |
| 2025-12-19 | Desjarlais John R | +73,367 | $12.51 | $917,821 |
| 2025-12-19 | Dahiyat Bassil I | -114,377 | - | - |
| 2025-12-19 | Dahiyat Bassil I | -114,377 | $15.71 | $1,796,863 |
| 2025-12-19 | Dahiyat Bassil I | +114,377 | $12.51 | $1,430,856 |